-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3891 Unique Nature of Sickle Cell Diastolic Cardiomyopathy: A Tailored Echocardiographic Definition to Refine Prognostic Stratification in Young Adults

Program: Oral and Poster Abstracts
Session: 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
Research, Epidemiology, Health outcomes research, Clinical Research
Monday, December 9, 2024, 6:00 PM-8:00 PM

Thomas D'Humieres, MD1,2*, Théo Simon, MD3*, Kristoffer Grundtvig Skaarup, MD4*, Laurent Savale, MD, PhD5*, Paul Breillat, MD6*, Jocelyn Inamo, MD, PhD7*, Gylna Loko, MD8*, Christelle Chantalat-Auger, MD9*, Anne-Laure Pham Hung D'Alexandry D'Orengiani, PhD10*, Anoosha Habibi, MD11,12,13, Gonzalo De Luna, MD14,15*, Niklas Dyrby Johansen, MD4*, François Lionnet, MD, PhD16*, Frederic Galacteros, Prof, MD17*, Etienne Audureau, MD, PhD18*, Mark T. Gladwin, MD19*, Tor Biering-Sørensen, MD, PhD20*, Geneviève Derumeaux, MD, PhD21* and Pablo Bartolucci, MD, PhD22,23,24,25*

1Physiology Department, FHU SENEC, INSERM IMRB U955, Henri-Mondor University Hospital- UPEC, AP-HP, Créteil, France
2Paris Cardiovascular Research Center - PARCC, Inserm team 8, Paris, France
3Henri Mondor teaching hospital, Physiology department, APHP, Créteil, France
4Department of Cardiology | Center for Translational Cardiology and Pragmatic Randomized Trials (CTCPR) & Cardiovascular Non-Invasive Imaging Research Laboratory (CIRL), Hellerup, Denmark
5Kremblin Bicêtre teaching hospital, Le Kremlin Bicêtre, FRA
6Paris Cardiovascular Research Center - PARCC, Inserm team 8, Université Paris Cité, Paris, France., Paris, France
7Department of Cardiology, University of the French West Indies and Guiana, Fort-de-France, Martinique, France., Fort-de-France, France
8CHU Martinique, Le Lamentin, Martinique
9Department of Internal Medicine, Bicetre Teaching Hospital, AP-HP, Universite Pa, Le Kremlin Bicetre, France
10University Paris-Est-Créteil, IMRB, Inserm U955, Laboratory of excellence LABEX, Henri Mondor University Hospitals, APHP, Sickle Cell Referral Center-UMGGR, Créteil, FRA
11Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital, APHP, Creteil Cedex, France
121 avenue Claude Vellefaux, ERN-EuroBloodNet, PARIS, France
13Sickle Cell Referral Center, Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital- UPEC, AP-HP, Creteil, France
14APHP, Paris, France
15Sickle Cell Referral Center, Department of Internal Medicine, Henri-Mondor University Hospital- UPEC, AP-HP, Creteil, France
16HôPital Tenon, Paris, FRA
17GHU Henri Mondor, AP-HP, Creteil, France
18Unité de Recherche Clinique, Henri-Mondor University Hospital- UPEC, AP-HP, Creteil, France
19Department of Medicine, University of Maryland School of Medicine, Baltimore, MD
20Department of Cardiology | Center for Translational Cardiology and Pragmatic Randomized Trials (CTCPR) & Cardiovascular Non-Invasive Imaging Research Laboratory (CIRL), Hellerup, DNK
21CHU Henri Mondor, FHU SENEC, Créteil, France
22Université Paris-Est Créteil, INSERM, IMRB, Laboratory of excellence LABEX GRex, Créteil, France
23University Paris-Est-Créteil, IMRB, Inserm U955,, Henri Mondor University Hospitals, APHP, Sickle Cell Referral Center-UMGGR, Creteil, France
24UMGGR French Red Blood Cell Coordinating Referral Center, APHP UPEC IMRB, Créteil, France
25Université Paris-Est Créteil, INSERM U955, IMRB, Laboratory of excellence LABEX GRex, Créteil, France

Background: Cardiovascular complications are the leading cause of mortality in sickle cell anemia (SCA) patients. While cardiac diastolic dysfunction (DD) is a well-documented mechanism contributing to heightened morbidity and mortality, the unique hemodynamic conditions inherent to SCA pose challenges to the application of standard diastolic evaluation methods. To date, there remains an absence of a suitable echocardiographic definition for early DD in SCA, which could significantly improve risk stratification and management strategies.

Methods: To refine the definition of diastolic dysfunction in SCA and propose an adapted echocardiographic definition of early SCA diastolic cardiomyopathy, we leveraged data from the French multicentric cohort Etendard alongside a matched subgroup from the Copenhagen City Heart Study (CCHS) cohort as control. Our investigation focused on early left ventricular (LV) diastolic impairment parameters, including e’ lateral wave (e’lat, marker or LV compliance), E/e’ ratio (hallmark of LV filling pressure), and indexed left atrial volume (LAVi). Then, a young subgroup within Etendard cohort was defined, among which age exerted no impact on diastolic function parameters, facilitating the formulation of an adapted definition for early DD. The 12-year prognosis was used to further define the optimal diastolic impairment definition.

Results: SCA patients from the Etendard cohort (n=379) exhibited significantly and early impaired diastolic function parameters compared to the matched CCHS subgroup (n=672). Among younger SCA patients (n=252, age≤38 years, mean age of 28±5 years, 57% females), e’lat emerged as the sole independent diastolic parameter associated with prognosis (p=0.01), with an optimal cut-off value of 11 cm/s selected for prognostic stratification and further defined as DD (Se=89%, Sp=50%, p=0.01). Strikingly, young SCA patients with DD exhibited a fourfold higher 12-year mortality rate (16 vs. 4%, p<0.001), mainly from cardiovascular causes. Consistantly with previous studies, e’lat (i.e diastolic function) correlated with 6-minute walking test (6MWT), NT pro-BNP levels, diastolic blood pressure, and lactate dehydrogenase levels. Three-year follow-up revealed a decline in 6MWT distance among the DD group, a more important GFR drop and a trend toward higher tricuspid regurgitation velocity.

Conclusion: In young SCA patients, diastolic function evaluation requires dedicated definition. Echocardiographic LV compliance evaluation using lateral e’ wave velocity demonstrates associations with key indicators of cardiac impairment, hemolysis, and systemic vasculopathy, with a value below 11 cm/s dramatically increasing 12-year mortality.

Disclosures: Habibi: Novartis: Consultancy; Theravia: Honoraria. De Luna: Pfizer: Other: Sponsor HEMOPROVE trial NCT05199766; Vertex: Consultancy. Galacteros: Agios: Consultancy; Vertex: Consultancy. Bartolucci: JazzPharma: Consultancy; Addmedica: Consultancy, Other: member advisory board; Novartis: Consultancy, Other: member advisory board and member steering commitee; Emmaus: Consultancy; Innovhem: Other: Founder; Pfizer: Consultancy; Bluebird: Consultancy; Roche: Consultancy.

*signifies non-member of ASH